Related Experiment Video
Updated: Jul 4, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Reovirus Reassortants Reveal Context-Dependent Oncolytic Phenotypes Across Epithelial Cancer Cell Lines
J Ryder Hutchinson1, Owen M Carter1, Charlotte V Dagli1
1Department of Biology, Elon University, Elon, North Carolina, USA.
Abstract:
Mammalian reoviruses are promising oncolytic agents, but most preclinical and clinical work has focused on the type 3 Dearing (T3D) prototype, potentially underestimating the therapeutic relevance of broader reovirus genetic diversity. Because reoviruses possess a segmented double-stranded RNA genome, reassortment can generate progeny with novel combinations of traits influencing infectivity, replication, and cytotoxicity. Here, we evaluated a panel of previously generated T1L × T3D reassortants and recombinant reoviruses across three epithelial tumor models: A549 lung adenocarcinoma and the oral squamous carcinoma cell lines OECM-1 and CAL-27. Across all three models, the tested viruses displayed marked cell line-dependent heterogeneity in both cytotoxicity and infectivity. Several reassortants reduced viability more effectively than the parental T1L and T3D strains in one or more cell lines, and DB62 emerged as the most broadly active candidate across the panel. Infectivity and cytotoxicity overlapped only partially, indicating that efficient infection alone does not fully predict oncolytic potency. Together, these findings show that reassortment can generate reoviruses with enhanced or selective activity across epithelial tumor contexts and support future studies examining how segment-dependent differences in interferon antagonism, entry, and cell death shape oncolytic potency.
Insights
Mammalian reoviruses show promise as oncolytic agents. Genetic reassortment can create novel reovirus strains with enhanced tumor-killing abilities, offering new therapeutic strategies.
Area of Science:
- Virology
- Oncology
- Molecular Biology
Background:
- Mammalian reoviruses are explored as oncolytic agents.
- Research has primarily focused on the type 3 Dearing (T3D) strain.
- Reovirus genetic diversity may hold untapped therapeutic potential.
Purpose of the Study:
- To evaluate a panel of reovirus reassortants and recombinants.
- To assess their efficacy in epithelial tumor models.
- To understand how genetic diversity impacts oncolytic activity.
Main Methods:
- Tested T1L × T3D reassortants and recombinant reoviruses.
- Utilized A549 lung adenocarcinoma and OECM-1/CAL-27 oral squamous carcinoma cell lines.
- Assessed viral cytotoxicity and infectivity across models.
Main Results:
- Observed significant cell line-dependent heterogeneity in cytotoxicity and infectivity.
- Identified reassortants with superior viability reduction compared to parental strains.
- DB62 demonstrated broad activity across tested epithelial tumor models.
Conclusions:
- Reassortment can generate reoviruses with enhanced or selective oncolytic activity.
- Infectivity does not fully predict oncolytic potency.
- Further research is needed on segment-dependent factors influencing reovirus efficacy.
Related Concept Videos
Viral Recombination
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

